Navigation Links
Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
Date:2/7/2008

SAN CARLOS, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it will hold the following events in February:

BIO CEO & Investor Conference

February 13, 2008

11:45 a.m. ET

Dr. Ted W. Love, Chairman and CEO
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NUVO&item_id=1752425

Fourth Quarter and Year End 2007 Financial Results and Accomplishments

Conference Call & Webcast

February 27, 2008

4:30 p.m. ET (1:30 p.m. PT)

Dr. Ted W. Love, Chairman and CEO

Dr. Michael Levy, EVP, Research and Development

Lee Bendekgey, SVP, Finance and CFO

Dial in: 866-854-8095 domestic and 706-634-8567 international with

passcode 32403438

Replay: 800-642-1687 domestic and 706-645-9291 international with passcode

32403438, available through Wednesday, March 12, 2008

Webcast: This call is being webcast by Thomson/CCBN and can be accessed via Nuvelo's website at http://www.nuvelo.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo's website at http://www.nuvelo.com.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... MedPro Waste Disposal, LLC ... service. MedPro now offers its mail back service for an all-inclusive rate. MedPro ... now able to provide service to all of the clients in the country who ...
(Date:5/2/2016)... Veendam, The Netherlands (PRWEB) , ... May 02, 2016 , ... ... Products is honored to announce that the new WHIMZEES Variety Value Boxes were selected ... EXPO 2016 New Product Showcase Award. , WHIMZEES natural dental chews for dogs ...
(Date:5/2/2016)... ... 02, 2016 , ... Dr. Rassouli, dentist in Orange County, CA ... the research, which was published in the “Journal of the American Geriatrics Society,” more ... million Americans have Alzheimer’s disease. The study found that dental problems may increase the ...
(Date:5/2/2016)... ... ... 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and Chris ... is being held in London, England this year from June 18-25. At the last WUGC ... in the women’s masters division, and a silver in the women’s division, so Mazur hopes ...
(Date:5/2/2016)... ... , ... According to an American Psychological Association article, the Centers ... the age of 18. Of those who survive, many still face effects as they ... In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
(Date:4/28/2016)... 28, 2016 TapImmune,Inc. (TPIV), ... peptide and gene-based immunotherapeutics and vaccines for the treatment of ... at the 3rd Annual Growth Capital Expo to ... 2016 at Caesars Palace in Las Vegas, Nevada.  The ... May 4 th by Dr. John N. Bonfiglio ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: